Horizon 2020 EarLy dEtection of cerVical cAncer in hard-to-reach populations: development and implementation of a new HPV test combining self-sampling.

Slides:



Advertisements
Similar presentations
Evaluation of ESF Support for Roma integration Dominique Bé EURoma, 10 November 2011, Budapest.
Advertisements

Incorporating considerations about equity in policy briefs What factors are likely to be associated with disadvantage? Are there plausible reasons for.
Cervical cancer screening in Estonia: present situation Piret Veerus Department of Epidemiology and Biostatistics National Institute for Health Development.
Cervical cancer screening problems and barriers in Latvia
Purposes and uses of cancer registration E.E.U. Akang Department of Pathology University College Hospital Ibadan, Nigeria.
PROJECT Situation analysis and cost- effectiveness analysis of cervical cancer screening in Russia Coordinator of the project: N. Koroleva.
Knowledge, Cancer Fatalism and Spirituality as Predictors of Breast Cancer Screening Practices for African American and Caucasian Women Staci T. Anderson,
FORESIGHT STUDY Future Trends and Challenges in Pathogenomics JUDITH SIMON & SVEN POMPE PROGRAMME GROUP MUT.
Assessing Minority Participation in Clinical Trials: Setting Attainable Goals The Minority and Women Clinical Trials Recruitment Program Department of.
Evaluation of Primary Versus Secondary Prevention of Cervical Cancer: an evidence based literature review Jennifer Vestle, PA-S, John Carter, PhD Department.
Operational Research in the 21 st Century. International Union Against Tuberculosis and Lung Disease (The Union) World’s oldest humanitarian organization.
HPV VACCINATION Dr Frida Mghamba 2 nd East Africa WE CAN Summit 11 th September 2014.
Cervical cancer screening: problems and barriers in Estonia Piret Veerus Department of Epidemiology and Biostatistics National Institute for Health Development.
EUROCHIP-2 results in Lithuania Varenna October 18, 2007 Presented by Ruta Kurtinaitiene
Cooperative Agreement Number U58/CCU U58DP Spirit Health Education (S.H.E.) Circle Early Detection or Survivorship of Cancer in Underserved.
This presentation is the intellectual property of the authors. Contact for permission to reprint and/or This.
Guidelines Recommandations. Role Ideal mediator for bridging between research findings and actual clinical practice Ideal tool for professionals, managers,
California Department of Public Health Office of AIDS HIV CARE and PREVENTION 2009: You Need to Know.
GENOMICS TO COMBAT RESISTANCE AGAINST ANTIBIOTICS IN COMMUNITY-ACQUIRED LRTI IN EUROPE (GRACE) H. Goossens (Coordinator), K. Loens (Manager), M. Ieven.
Georgia Comprehensive Cancer Control Program 3/10/2015 Program Monitoring and Evaluation Activities Short-Term Outcomes Long-Term Outcomes Intermediate.
Scottish Improvement Science Collaborating Centre Strengthening the evidence base for improvement science: lessons learned Dr Nicola Gray, Senior Lecturer,
Can an evidence based coaching intervention improve outcomes for older people with congestive heart failure (CHF) and their informal caregivers within.
Comparative Effectiveness Research (CER) and Patient- Centered Outcomes Research (PCOR) Presentation Developed for the Academy of Managed Care Pharmacy.
European network for Health Technology Assessment | JA | EUnetHTA European network for Health Technology Assessment THL Info.
Table 1. Methodological Evaluation of Observational Research (MORE) – observational studies of incidence or prevalence of chronic diseases Tatyana Shamliyan.
Cancer prevention and early detection
Public Health England leads the NHS Screening Programmes
Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions ELINA VIRTANEN1, ILKKA KALLIALA2,3,
Title Investigators and sites. Clinical Trial Proposal Presentation Template for open forum at the 2017 ASM.
Seroprevalence, prevalence, type and factors associated with HPV infection at multiple sites in young HIV-positive MSM On behalf of the HPV MAPS Research.
Tackling Inequalities in Screening
Development of a Simplified MUAC Bracelet: the Click-MUAC Project
DATA COLLECTION METHODS IN NURSING RESEARCH
University of Rajarata.
HEE Nursing Associate Programme
Presentation Developed for the Academy of Managed Care Pharmacy
NCD in Bulgaria Assoc. Prof. Plamen Dimitrov, MD, PhD
Addressing Breast Health Inequalities Among Women with Disabilities
Evaluation of 15 projects – ‘Supporting School Leavers’
Isabel C. Scarinci, PhD, MPH University of Alabama at Birmingham
Milkie Vu, MA Research Specialist The University of Chicago
Cervical Cancer prevention among women in Vlora city: the influence of fear-related to possible positive outcomes Authors: 1*Fatjona Kamberi RN, MSN,
HPV vaccination for men
A Path of Learning and Improvement
Obstetrician and Gynecologist Malawi Inaugural Cancer Symposium
Maya B. Mathur Castilleja School, Palo Alto, CA
Cancer 101: A Cancer Education and Training Program for [Target Population] Date Location Presented by: Presenter 1 Presenter 2 1.
Born too soon Worldwide, every year 15 million babies are born too soon (= before week 37 of pregnancy), that is more than 1 baby in 10 ≈ very.
Call topic identification for 2019 call
Presentation Developed for the Academy of Managed Care Pharmacy
Cancer Research Early Diagnosis Research Conference: ECR Pechakucha presentation: Feb 2017 Exploring patient and practitioner perspectives of QCancer.
PAST, PRESENT AND FUTURE
Web site: BioSciCon, Inc. Business Opportunity 2006 Web site: January 15, 2019.
Standard 3.1 Patient Navigation Process
Public Health England leads the NHS Screening Programmes
Sacurima – CA Safety Culture and Risk Management in Agriculture.
Introduction Acknowledgments Identified need Project objective
Evaluation of Programs
National Cancer Center
What existing research and data can tell us
Why do we need ImpleMentAll?
Knowledge, Attitudes, and Practices Regarding Cervical Cancer and Screening Dr Ghufran Jassim MBBS,MD, MSc, PhD 8/30/2017.
Engaging all care providers
Sacurima – CA Safety Culture and Risk Management in Agriculture.
Including People with Disabilities: Public Health Workforce Competencies Module 3 Competency 2: Discuss methods used to assess health issues for people.
Cervical Screening Programme
Isabel C. Scarinci, PhD, MPH James Kendrick, MD Edward Partridge, MD
African American and Hispanic Females and the Need for Early Detection
Presentation Developed for the Academy of Managed Care Pharmacy
TRIFOLD AREA – THIS GUIDE WILL BE REMOVED BEFORE PRINTING – TRIFOLD AREA – THIS GUIDE WILL BE REMOVED BEFORE PRINTING – TRIFOLD AREA – THIS GUIDE WILL.
Presentation transcript:

Horizon 2020 EarLy dEtection of cerVical cAncer in hard-to-reach populations: development and implementation of a new HPV test combining self-sampling with a low-cost, portable and point-of-care device (ELEVATE) Sónia Dias, Ana Gama, Ines Keygnaert, Katrina Perehudoff, Heleen Vermandere, Olivier Degomme This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant No 825747

Cervical cancer screening coverage Cervical cancer is the fourth most common cancer in women in the world. Human Papillomavirus (HPV) is the main cause > 150 HPV types (high-risk types, low-risk types) Early detection through cancer screening can improve survival. Cervical cancer screening coverage Brazil: 71% Portugal: 71% Belgium: 62% Ecuador: 9% Screening rates tend to be much lower among women in rural areas, from low socio-economic backgrounds or from ethnic minorities

Challenges for cervical cancer screening Cervical cytology continues to be the primary screening method (sampling cells from the cervix by a specialized gynecologist and evaluating the presence of potential cell abnormalities related to cervical cancer under a microscope) - low sensitivity. HPV DNA testing has been endorsed as an effective and low-cost primary screening method (higher sensitivity), however: Current HPV DNA tests can only discriminate between some high-risk HPV infections and cannot determine HPV infection with multiple HPV genotypes; Current cervical cancer screening tools are not available, acceptable, and/or cost-effective for hard-to-reach women, resulting in under-screening.

Objectives To identify hard-to-reach women and define a strategy to increase their participation in Belgium, Brazil, Ecuador, Portugal Target population To improve detection of infections by designing a HPV genotyping test with detection of 2 protein cervical cancer biomarkers Test design To develop a portable genomic/proteomic testing device using the now test for detection at point-of-care in low-resource settings Device development To determine the user-acceptability and cost-effectiveness of the new screening intervention in Belgium, Brazil, Ecuador, Portugal Societal impact

How to reach hard-to-reach women

Identify hard-to-reach populations Goal - To identify hard-to-reach women for cervical cancer screening in the study countries. Methodology - Triangulation of sources: Academic literature, government and NGO reports (grey literature), policy documents – accessed through systematic online search; Anonymised patient registries and/or insurance databases that permit the characterisation of under- or never-screened women. Focus group discussions Goal – To understand barriers and facilitators of hard-to-reach women’s participation in conventional cervical screening and to explore alternative strategies to enhance their participation, including self-sampling. Methodology – 12 focus groups (3 FG in each study country): 8 FG with women from hard-to-reach populations 4 FGs with screening/health professionals

Design strategies to pilot the HPV detection device in hard-to-reach populations Goal – To develop country-specific strategies to inform the study design of the pilot intervention Methodology Target group: women from socially vulnerable hard-to-reach populations. The strategy will include: approaches to build rapport with the target women (based on partners’ experience and expertise of working with these populations) Design of the screening intervention to test the HPV detection device in an acceptable manner for the target women

HPV genetic variability analysis

Collect cervical specimens Goal – To collect cervical specimens in the study countries for HPV sequencing and test validation Methodology – collection of 250 samples among women > 30 years old who have not been screened during the last 5 years and belong to an identified subgroup of hard-to-reach women 150 samples with high prevalence of high risk HPV 50 samples with low prevalence of high risk HPV 50 samples - normal cytology

Design of HPV detection test Proteomic and genomic HPV screening sensor development Microfluidic cartridge and screening tools development

Pilot the HPV testing intervention in hard-to-reach communities

Piloting the new testing device Goal – to estimate user take-up of new screening strategy and assess the user take-up and acceptability of a HPV self-sampling and testing Methodology Recruiting and training community based researchers 3-arm prospective intervention study: Group 1 (control): local coverage of screening Group 2: 125 women receive info about cervix cancer and are referred to local clinics for screening Group 3: 125 women receive information about cervix cancer and are offered on-site HPV testing and results Interviews with participants of Group 3 to understand the users’ perspective and satisfaction Interviews with health care providers about their beliefs and attitudes towards the self-screening device

Economic analysis of the intervention

Horizon 2020 EarLy dEtection of cerVical cAncer in hard-to-reach populations: development and implementation of a new HPV test combining self-sampling with a low-cost, portable and point-of-care device (ELEVATE) THANK YOU sonia.dias@ensp.unl.pt ana.gama@ensp.unl.pt This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant No 825747